No standard treatment for unresectable or recurrent pseudomyxoma peritonei has been defined. Our study showed that metronomic capecitabine with cyclophosphamide is a well tolerated and potentially active regimen in this disease setting. Neutrophil to lymphocyte ratio baseline < 3, compared with ≥ 3, showed a significant association with a prolonged progression-free survival.
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei
Cremolini C.;Marmorino F.;
2019-01-01
Abstract
No standard treatment for unresectable or recurrent pseudomyxoma peritonei has been defined. Our study showed that metronomic capecitabine with cyclophosphamide is a well tolerated and potentially active regimen in this disease setting. Neutrophil to lymphocyte ratio baseline < 3, compared with ≥ 3, showed a significant association with a prolonged progression-free survival.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
